Sacituzumab govitecan for metastatic or unresectable locally advanced triple-negative breast cancer – third line

Sacituzumab govitecan is in clinical development for the treatment of adult patients with metastatic or unresectable locally advanced triple-negative breast cancer (TNBC) who have received at least two prior therapies. TNBC patients tend to have worse clinical outcomes than non-TNBS groups due to its high-risk biological characteristics and lack of effective treatments.
Sacituzumab, a type of molecule called a monoclonal antibody, targets the Trop-2 protein; which is found in more than 90% of TNBCs. Sacituzumab govitecan is an antibody-drug conjugate. The linking compound attaches (conjugates) the monoclonal antibody sacituzumab to the SN-38 chemotherapy. Sacituzumab govitecan is administered as an intravenous infusion. If licensed, sacituzumab govitecan will offer an additional treatment option for adult patients with metastatic or unresectable locally advanced TNBC who have received at least two prior therapies.